Locally advanced or metastatic breast cancer who have progressed after at least 1 chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline & a taxane in either adjuvant or metastatic setting unless patients were not suitable for these treatments. Soft tissue sarcoma.
1.4 mg/m2 IV over 2-5 min on days 1 & 8 of every 21-day cycle. Patient w/ mild hepatic impairment (Child-Pugh A) 1.1 mg/m2 IV over 2-5 min on days 1 & 8 of a 21-day cycle. Moderate hepatic impairment (Child-Pugh B) 0.7 mg/m2 IV over 2-5 min on days 1 & 8 of a 21-day cycle.
Monitor complete blood count prior to each dose. Higher incidence of grade 4 & febrile neutropenia in patients w/ ALT or AST >3 x ULN or bilirubin >1.5 x ULN. Peripheral neuropathy. Avoid in patients w/ congenital long QT syndrome & perform ECG to patients w/ CHF, bradyarrhythmias, concomitant use of drugs that prolong QT interval including class Ia & III antiarrhythmics & electrolyte abnormalities. Hypokalemia & hypomagnesemia should be corrected prior to initiation & monitored periodically during therapy. Concomitant use w/ anti-HER2 therapy. Contains small amounts of ethanol (alcohol) <100 mg/dose. Possibility of irreversible infertility in male patients. May affect ability to drive or operate machinery. Pregnancy.
Sign Out
